“Over the last 16 years, The Ottawa Hospital’s Biotherapeutics Manufacturing Centre has played a critical role in manufacturing vaccines, stem cells and virus-based therapies for clinical trials around the world and we look forward to working with partners to leverage this success.” Duncan Stewart, Executive Vice-President of Research at The Ottawa Hospital and professor at the University of Ottawa. “We are delighted to have this opportunity to contribute to Canada’s growing bioscience and biomanufacturing ecosystem,” said Dr. “We’re perfectly positioned to co-lead this initiative and work with our industry and academic partners to support both Canada’s and Ontario’s life sciences strategy, expand our innovation ecosystem and bridge the gap between lab and market.” “McMaster is on the leading-edge of pandemic-related research at Canada’s Global Nexus for Pandemics and Biological Threats, adding that Hamilton – driven, in part, by the McMaster Innovation Park – is one of the country’s fastest growing life sciences clusters, “said Karen Mossman, vice-president, Research at McMaster University. “The ultimate goal is to make Canada a global leader in emerging vaccines, therapeutics and diagnostics, enhancing the national capacity to prevent and respond to future pandemics.” ![]() “We are very eager to actively contribute to this groundbreaking national effort to grow a strong and competitive biomanufacturing and life sciences sector,” said Sylvain Charbonneau, vice-president, Research and Innovation at the University of Ottawa. The CP 2H lead scientists are “academic entrepreneurs” who have organized national team projects and led the design, building and acquisition of the specialized infrastructure that is key to our hub’s ultimate success. This new hub brings together highly collaborative investigators from across Canada with complementary research interests and a demonstrated track record of working together. The Canadian Pandemic Preparedness Hub is a network that will ensure Canadian discoveries are turned into the medicines of tomorrow in a cost-effective and timely fashion. ![]() This is a national competition that includes $570 million in available funding for proposals, aimed at cutting-edge research, talent development and research infrastructure projects associated with the selected research hubs. Today’s announcement also launched Stage 2 of the CBRF-BRIF funding opportunity. ![]() These two investments are part of the Government of Canada’s Canada’s Biomanufacturing and Life Sciences Strategy, a $2.2 billion funding initiative over seven years to continue growing a strong, competitive biomanufacturing and life sciences sector, and to ensure Canada is prepared for future pandemics.ĬP 2H will be a strategic partner to support Canada in becoming internationally competitive in the translation of novel biotherapeutic discoveries made in academic laboratories and industry into clinical testing and commercialization. The CP 2H, co-led by uOttawa, in partnership with The Ottawa Hospital and McMaster University, is one of the five research hubs selected following the Stage 1 of the integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) funding opportunity totalling $10 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |